Ireland-based Endo International plc (NASDAQ: ENDP) announced on Friday that its subsidiary Endo Ventures Limited has signed contract with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX), an Israel-based specialty pharmaceutical company, for the development, registration, supply, commercialisation and distribution of Quoin's QRX003 on an exclusive basis in Canada.
QRX003 is Quoin's lead product for Netherton syndrome, a rare, hereditary disorder.
If QRX003 receives approval, Paladin Labs Inc., an Endo operating company, will handle all commercial activities in Canada. Presently, Paladin is expecting to introduce the product in Canada in 2025.
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership
Vicinitas Therapeutics Launches with USD 65m in Series A Financing